| __timestamp | ADMA Biologics, Inc. | Agios Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 19120000 |
| Thursday, January 1, 2015 | 6745968 | 35992000 |
| Friday, January 1, 2016 | 8494742 | 50714000 |
| Sunday, January 1, 2017 | 18092835 | 71124000 |
| Monday, January 1, 2018 | 22502922 | 114145000 |
| Tuesday, January 1, 2019 | 25910757 | 132034000 |
| Wednesday, January 1, 2020 | 35050817 | 149070000 |
| Friday, January 1, 2021 | 42896889 | 121445000 |
| Saturday, January 1, 2022 | 52458024 | 121673000 |
| Sunday, January 1, 2023 | 59020000 | 119903000 |
| Monday, January 1, 2024 | 156784000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, ADMA Biologics, Inc. and Agios Pharmaceuticals, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, ADMA Biologics saw a steady increase in SG&A expenses, starting at approximately $4.8 million and reaching nearly $59 million by 2023. This represents a growth of over 1,100%, reflecting their aggressive expansion strategy.
Conversely, Agios Pharmaceuticals began with higher SG&A costs, around $19 million in 2014, peaking at $149 million in 2020, before slightly reducing to $119 million in 2023. This fluctuation indicates a more volatile approach, possibly due to strategic shifts or market conditions. Understanding these trends offers valuable insights into how each company navigates financial management in a dynamic industry.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and ADMA Biologics, Inc.
Regeneron Pharmaceuticals, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Exelixis, Inc. vs Agios Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc or Agios Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Lantheus Holdings, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Ionis Pharmaceuticals, Inc. or Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and Viking Therapeutics, Inc.
Selling, General, and Administrative Costs: ADMA Biologics, Inc. vs HUTCHMED (China) Limited
Apellis Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Merus N.V. and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Supernus Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Mesoblast Limited and Agios Pharmaceuticals, Inc.